IL17A and inflammatory bowel disease: Furthermore, we also showed that therapeutic FMT administration in the context of a chronic experimental colitis setting, a condition more similar to that of IBD patients, stably decreased colonic inflammation by modulating the expression of pro-inflammatory genes, such as Ifng, Tnf, Il1b, Il-17, and Il-6 [107].